# enVVeno Medical Corp: overview NVNO · Nasdaq · CIK 1661053 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/nvno.md) · [Financials](/companies/nvno/financials.md) · [Filings](/companies/nvno/filings.md) · [Insiders](/companies/nvno/insiders.md) Latest reported revenue: [$0](/filings/0001493152-21-007526.md) for Q4 FY2019, three months to 2019-12-31, from the 10-K filed Mar 31, 2021 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-21-007526). ## Last eight quarters | Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | [(7.75)](/filings/0001493152-26-021490.md) | [(11.52)](/filings/0001493152-26-035452.md) | [(7.89)](/filings/0001493152-26-049269.md) | not reported | [(5.89)](/filings/0001493152-26-021490.md) | [(5.37)](/filings/0001493152-26-035452.md) | [(6.29)](/filings/0001493152-26-049269.md) | | Free cash flow | $k | [(5,109) d](/filings/0001493152-26-012928.md) | not reported | not reported | [(4,392) d](/filings/0001493152-26-049269.md) | [(3,443) d](/filings/0001493152-26-012928.md) | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.90)](/filings/0001493152-22-007802.md) | [(2.20)](/filings/0001493152-24-008336.md) | [(1.91)](/filings/0001493152-25-008739.md) | [(44.53)](/filings/0001493152-26-012928.md) | [(33.06)](/filings/0001493152-26-012928.md) | | Free cash flow | $m | [(12.2)](/filings/0001493152-23-006587.md) | [(15.7)](/filings/0001493152-24-008336.md) | [(18.9)](/filings/0001493152-25-008739.md) | [(16.9)](/filings/0001493152-26-012928.md) | [(15.6)](/filings/0001493152-26-012928.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/nvno/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [KINGDON CAPITAL MANAGEMENT, L.L.C.](/funds/1000097.md) | 2026-06-30 | $387.3k | 36,166 | | Unchanged | | [CM Management, LLC](/funds/1841857.md) | 2026-06-30 | $382.5k | 35,714 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $67.4k | 6,287 | | Unchanged | | [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $59.1k | 5,208 | | Reduced −1 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $23.4k | 2,184 | | Unchanged | | [Westside Investment Management, Inc.](/funds/1538383.md) | 2026-06-30 | $16.3k | 1,525 | | Reduced −64 | | [Mirae Asset Global Investments Co., Ltd.](/funds/1569395.md) | 2026-06-30 | $5.8k | 539 | | New +539 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $4.4k | 414 | | Reduced −1,426 | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $3.5k | 331 | | Reduced −211 | | [WELLS FARGO & COMPANY/MN](/funds/72971.md) | 2026-06-30 | $1.2k | 114 | | Unchanged | ## Recent filings [All 415 filings](/companies/nvno/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-29 | 17:00 ET | [DEF 14A](/filings/0001140361-26-041182.md) | Proxy statement, period 2026-12-10 | 0001140361-26-041182 | | 2026-10-29 | 16:05 ET | [10-Q](/filings/0001493152-26-049269.md) | Quarterly report, period 2026-09-30 | 0001493152-26-049269 | | 2026-09-15 | 16:01 ET | [SCHEDULE 13D/A](/filings/0001213900-26-100114.md) | Ownership report, active investor, amended | 0001213900-26-100114 | | 2026-07-30 | 16:05 ET | [10-Q](/filings/0001493152-26-035452.md) | Quarterly report, period 2026-06-30 | 0001493152-26-035452 | | 2026-07-14 | 16:55 ET | [8-K](/filings/0001493152-26-033193.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-033193 | | 2026-05-06 | 16:10 ET | [10-Q](/filings/0001493152-26-021490.md) | Quarterly report, period 2026-03-31 | 0001493152-26-021490 | | 2026-04-29 | 08:25 ET | [8-K](/filings/0001493152-26-019485.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-019485 | | 2026-03-26 | 16:24 ET | [10-K](/filings/0001493152-26-012928.md) | Annual report, period 2025-12-31 | 0001493152-26-012928 | | 2026-02-20 | 09:43 ET | [SCHEDULE 13D](/filings/0001213900-26-018626.md) | Ownership report, active investor | 0001213900-26-018626 | | 2026-02-20 | 09:43 ET | [SCHEDULE 13D](/filings/0001213900-26-018625.md) | Ownership report, active investor | 0001213900-26-018625 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-012928.md), filed Mar 26, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1661053 - Tickers: NVNO - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 19:27 ET. No prices; not investment advice.